[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550406":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":39,"centralContacts":43,"locations":49,"responsibleParty":68,"collaborators":30,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":30,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":30,"enrollmentInfo":79,"targetDuration":30,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":52,"whyStopped":30,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Chicago","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Efficacy Phase: High Intensity Messaging","ACTIVE_COMPARATOR","Receives high-intensity text messaging for 2 cycles of treatment",[13],"Other: High Intensity",{"label":15,"type":10,"description":16,"interventionNames":17},"Efficacy Phase: Low Intensity Messaging","Receives no texts for 1st cycle and low-intensity texts for 2nd cycle",[18,19],"Other: No Text Messagings","Other: Low Intensity Text Messaging",{"label":21,"type":22,"description":23,"interventionNames":24},"Pilot Phase Arm","EXPERIMENTAL","Participants receive high-intensity text messaging for 28 days",[13],[26,31,35],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"High Intensity","Daily texts",[9,21],null,{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"No Text Messagings","Standard Care",[15],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Low Intensity Text Messaging","Weekly Texts",[15],[40],{"name":41,"affiliation":5,"role":42},"Austin Wesevich","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":30,"email":48},"Clinical Trials Intake","CONTACT","1-855-702-8222","cancerclinicaltrials@bsd.uchicago.edu",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"University of Chicago Medicine Comprehensive Cancer Center","RECRUITING","Chicago","Illinois","60637","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-87.65005,41.85003,{"lat":62,"lon":61},[65,67],{"name":45,"role":46,"phone":66,"phoneExt":30,"email":48},"855-702-8222",{"name":41,"role":42,"phone":30,"phoneExt":30,"email":30},{"type":69,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100550406","using-text-messages-to-improve-oral-chemotherapy-for-adolescents-and-adults-with-acute-lymphoblastic-leukemia-100550406",false,"NCT06446661","Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia","Improving Oral Chemotherapy Adherence in Maintenance for Adolescents and Adults With Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Using Text Messages","Inclusion Criteria:\n\n* Age of 15 years or older at time of enrollment\n* Diagnosed with ALL or T-cell lymphoblastic lymphoma\n* Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention.\n\nExclusion Criteria:\n\n* Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages\n* Patient does not wish to participate\n* Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.","ALL","15 Years",{"count":80,"type":81},48,"ESTIMATED","INTERVENTIONAL",[84],"NA","This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.",[87,88],"Acute Lymphoblastic Leukemia","T-cell Lymphoblastic Lymphoma",[90],"Oral Chemotherapy","2026-07-08",{"date":93,"type":94},"2026-07-10","ACTUAL",{"date":96,"type":94},"2026-05-19",{"date":98,"type":81},"2028-06-15",{"name":5,"class":6},1]